Based on the evidence regarding the potential therapeutic effect of HHMX in SAVI patient blood, we next tested the therapeutic potential of HHMX in SAVI mice bearing heterozygous STING N153S mutation (Supplementary Figure 3B). Here, STING1 is linked to STING-associated vasculopathy with onset in infancy.